Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
By Michael Erman
NEW YORK, Sept 14 (Reuters) -Pfizer PFE.N is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates could grow to become the standard of care.
The company presented three-year follow-up data from a Phase 2 study on Saturday looking at patients with BRAF V600E-mutant metastatic non-small cell lung cancer who received Braftovi and another Pfizer drug, Mektovi, as a first treatment. The study showed they had a median of over two-and-a-half years of progression-free survival, a measure of how long treated patients live before their cancer gets worse.
Chris Boshoff, Pfizer's Chief Oncology Officer, said the new data supports the use of the drug as standard of care for that group and said it expects to get market penetration of up to 60% in lung cancer patients with the mutation.
He said approximately 2% to 3% of lung cancers have the mutation in question.
Standard of care for such patients is currently an immunotherapy paired with chemotherapy, Boshoff said. The combination of Braftovi and Mektovi has been approved for patients with non-small cell lung cancer with the mutation since last year.
"All patients with lung cancer should be tested for BRAF mutations, and that could be done with a simple blood test," he said. "It's a relatively easy test to identify these patients who clearly would benefit significantly from having a targeted therapy."
He said that fewer than 50% of lung cancer patients in the U.S. are currently tested for the mutation. That number is even lower globally.
"This is a space where Pfizer is particularly well equipped, not just in the US, but globally, to encourage testing and to help educate physicians, pathologists, patients, and patient advocate groups," Boshoff said. He said the test is covered by insurance in the U.S.
Pfizer sold close to $400 million of Braftovi and Mektovi last year, but analysts are not currently forecasting significant growth for the drugs, according to LSEG data.
One area where Boshoff said Braftovi could expand its market is in colorectal cancer, where BRAF-mutated cancers make up 10% of the cancers. Data from the company's late-stage study in colorectal cancer is expected to be announced by the end of the year, he said.
Reporting by Michael Erman, Editing by Rosalba O'Brien
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
